Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant in women with advanced ER+ HER2- breast cancer: The SERENA-2 trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 22nd 2022

The SERENA-2 trial (NCT04214288) is a randomised, multicentre phase II trial evaluating camizestrant at several dose levels compared to fulvestrant in advanced ER-positive, HER2-negative breast cancer. In this touchONCOLOGY interview, we speak with Dr Mafalda Oliveira (Vall d’Hebron University Hospital Barcelona, Spain) who gives an overview of the SERENA-2 trial and the advantages for the use of camizestrant over fulvestrant as well as discussing the next steps in the clinical development of camizestrant.

The abstract entitled ‘Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.

Questions:

  1. What is camizestrant and what are its potential advantages over fulvestrant in the treatment of post-menopausal women with advanced ER-positive HER2-negative breast cancer? (0:18)
  2. What were the aims, design and eligibility criteria of the SERENA-2 trial? (1:18)
  3. What was the primary endpoint and how well was it achieved across the pre-specified subgroups of urgent medical need? (2:39)
  4. What were the safety and tolerability findings? (4:43)
  5. What will be the next steps in the clinical development of camizestrant? (5:43)

Disclosures: Mafalda Oliveira is a consultant for AstraZeneca, GuardantHealth, Roche, MSD, Relay Therapeutics, Pfizer, SeaGen, iTEOS and Gilead and discloses grant/research support from AstraZeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Genentech, GSK, Novartis, PUMA Biotechnology, Roche, SeaGen and Zenith Epigenetics.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen

Filmed as a highlight of SABCS 2022

Access more content on Breast Cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup